- Home
- CANF vs PPBT Comparison
CANF vs PPBT Comparison
Compare CANF & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- PPBT
- Stock Information
- Founded
- CANF 1994
- PPBT 2010
- Country
- CANF Israel
- PPBT Israel
- Employees
- CANF N/A
- PPBT N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- PPBT Health Care
- Exchange
- CANF Nasdaq
- PPBT Nasdaq
- Market Cap
- CANF 7.9M
- PPBT 7.1M
- IPO Year
- CANF N/A
- PPBT N/A
- Fundamental
- Price
- CANF $1.18
- PPBT $2.71
- Analyst Decision
- CANF Strong Buy
- PPBT Strong Buy
- Analyst Count
- CANF 2
- PPBT 1
- Target Price
- CANF $14.00
- PPBT $33.00
- AVG Volume (30 Days)
- CANF 408.4K
- PPBT 15.8K
- Earning Date
- CANF 05-06-2025
- PPBT 05-20-2025
- Dividend Yield
- CANF N/A
- PPBT N/A
- EPS Growth
- CANF N/A
- PPBT N/A
- EPS
- CANF N/A
- PPBT N/A
- Revenue
- CANF $674,000.00
- PPBT N/A
- Revenue This Year
- CANF $461.72
- PPBT N/A
- Revenue Next Year
- CANF N/A
- PPBT N/A
- P/E Ratio
- CANF N/A
- PPBT N/A
- Revenue Growth
- CANF N/A
- PPBT N/A
- 52 Week Low
- CANF $1.22
- PPBT $2.00
- 52 Week High
- CANF $4.69
- PPBT $20.60
- Technical
- Relative Strength Index (RSI)
- CANF 37.60
- PPBT 52.21
- Support Level
- CANF $1.14
- PPBT $2.30
- Resistance Level
- CANF $1.27
- PPBT $2.89
- Average True Range (ATR)
- CANF 0.12
- PPBT 0.19
- MACD
- CANF -0.02
- PPBT 0.05
- Stochastic Oscillator
- CANF 6.03
- PPBT 70.05
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.